Biotechnology News Idiopathic Juvenile Osteoporosis Search

| Biotechnology feed | All feeds

BioNews
Biotechnology, Pharmaceutical and Life Science News

Search Results

Documents 1-6 out of 6 found

Current Search: idiopathic: 78, juvenile: 163, osteoporosis: 326

Possible Environmental Determinants of Juvenile Idiopathic Arthritis
In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.

To find out how to adjust your browser settings to accept cookies, please click here.

Medscape uses cookies to customize the site based on the information...

General Medicine eJournal: Mar 12 2010 10:47AM
Matching: idiopathic juvenile

Find similar documents

Possible Environmental Determinants of Juvenile Idiopathic Arthritis
What is currently known about environmental risk factors for the development of Possible Environmental Determinants of Juvenile Idiopathic Arthritis.

Medscape: Mar 12 2010 12:06AM
Matching: idiopathic juvenile

Find similar documents

Long-Term Abatacept Safe, Usually Effective for Juvenile Idiopathic Arthritis
_ Long-Term Abatacept Safe, Usually Effective for Juvenile Idiopathic Arthritis.

Abstracts in Hematology and Oncology: Mar 9 2010 9:10PM
Matching: idiopathic juvenile

Find similar documents

Long-Term Abatacept Safe, Usually Effective for Juvenile Idiopathic Arthritis
_ Long-Term Abatacept Safe, Usually Effective for Juvenile Idiopathic Arthritis.

Medscape: Mar 9 2010 8:15PM
Matching: idiopathic juvenile

Find similar documents

Outcome for juvenile idiopathic arthritis
Davidson J et al.

Juvenile Idiopathic Arthritis (JIA) is a heterogeneous group of chronic inflammatory conditions comprising several disease subtypes with a widely variable clinical course and outcome.

An ideal treatment outcome is one where...

MDLinx: Feb 17 2010 10:23AM
Matching: idiopathic juvenile

Find similar documents

European Commission Approves ORENCIA (abatacept) in Combination with Methotrexate for Children with Moderate to Severe Polyarticular Juvenile Idiopathic Arthritis (pJIA)
ORENCIA is a first-in-class biologic treatment option now available, in combination with methotrexate, for treatment of pJIA in paediatric patients aged six years and olderPARIS--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY - News) today announced...

Business Wire via Yahoo!: Jan 25 2010 5:00PM
Matching: idiopathic juvenile

Find similar documents

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.